Yang Shi

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi‐Long Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology · 2014 · 2K citations

Medicine, Oncology, Pharmacology +11

Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor

Hongcheng Lv, Yang Shi, Li Zhang et al. · BMC Cancer · 2014 · 118 citations · Full text

Medicine, Cell Biology, Oncology +17

LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.

Yi‐Long Wu, Caicun Zhou, Chengping Hu et al. · Journal of Clinical Oncology · 2013 · 83 citations

Medicine, Oncology, Pharmacology +13

Relation of Low Vitamin D to Nonvalvular Persistent Atrial Fibrillation in Chinese Patients

Wei Ren Chen, Zhi Ying Liu, Yang Shi et al. · Annals of Noninvasive Electrocardiology · 2013 · 65 citations · Full text

Medicine, Cardiology, Nutritional Sciences +17

Comparison between the effects of normoxia and hypoxia on antioxidant enzymes and glutathione redox state in ex vivo culture of CD34+ cells

Jinli Fan, Haibo Cai, Yang Shi et al. · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · 2008 · 61 citations

Life Sciences, Biochemistry, Cell Biology +17